Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 5/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | EP300 | Q09472 | 2/20 | 0.56 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985545 | 0.91 | ADCY5 (0.63) | ADCY5ADORA2AADORA1ADORA2BNSD3 | |
| SCHEMBL6045652 | 0.87 | EP300 (0.72) | ADCY5ADORA2AADORA1ADORA2BEP300 | |
| SCHEMBL6045566 | 0.87 | EP300 (0.72) | ADCY5ADORA2AADORA1ADORA2BEP300 | |
| SCHEMBL6045746 | 0.84 | ADCY5 (0.74) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL6045654 | 0.84 | EP300 (0.66) | ADCY5ADORA2AADORA1ADORA2BEP300 | |
| SCHEMBL6045700 | 0.84 | ADCY5 (1.00) | ADCY5ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL6045556 | 0.83 | ADCY5 (0.75) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL6045717 | 0.83 | ADCY5 (0.75) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL6694591 | 0.83 | EGFR (0.60) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL6045760 | 0.82 | ADCY5 (1.00) | ADCY5ADORA2AADORA1ADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
| US-6887880-B2 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20020068745-A1 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002040481-A2 | ADENINE BASED INHIBITORS OF ADENYLYL CYCLASE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068745-A1 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | CD38, ADCY1, ADCY2 | ADCY5 4/4885ADORA2A 38/4885ADORA1 27/4885 |
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | ADCY5 1/4885ADORA2A 303/4885ADORA1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.